The rate of severe hypoglycemia was 4.9 events per patient-year, and up to 5% of HAT study participants reported being admitted to the hospital for hypoglycemia during the 4-week study period.7 Hypoglycemia places a substantial cost burden on the individual and society and poses a major barrier to achieving and maintaining optimal blood glucose levels.6–8 However, the increased risk of diabetes complications resulting from chronic hyperglycemia could also be considered a cost for patients who avoid intensifying insulin therapy for fear of hypoglycemia. The gene discussed is INS; the disease is diabetes mellitus.